1994 Volume 42 Issue Supplement4 Pages 749-755
We evaluated the clinical efficacy and safety of biapenem (BIPM) in 18 patients with respiratory tract infection. BIPM was administered to 7 patients with pneumonia, 2 with bronchopneumonia, 1 with lung abscess, 4 with exacerbation (bronchiectasis), 2 with exacerbation (diffuse panbronchiolitis) and 2 with secondary infection. The daily dose was 0.6-1.2g and duration was 4-14 days. The following results were obtained.
1) The clinical efficacy of BIPM was excellent in 5, good in 11, fair in 1, poor in 1.
2) Of 7 strains (6 species) isolated from 7 cases before treatment, 5 strains were eradicated after treatment, but S. aureus persisted, and Haemophilus sp. was unknown.
3) No side effect were observed during treatment in 19 patients. As abnormal laboratory findings, elevation of GOT·EGPT and eosinophilia were observed in each two cases.
The above results suggest that BIPM is a valuable and safe agent for treating, respiratory tract infection.
